Perspective Therapeutics (CATX) Receives a Buy from Truist Financial
In a report released today, Nicole Germino from Truist Financial maintained a Buy rating on Perspective Therapeutics (CATX – Research Report).
Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX), Axsome Therapeutics (AXSM) and HCA Healthcare (HCA)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Perspective Therapeutics (CATX – Research ...
Wedbush Reaffirms Outperform Rating for Perspective Therapeutics (NYSE:CATX)
Wedbush reissued their outperform rating on shares of Perspective Therapeutics (NYSE:CATX – Free Report) in a report released ...
Unicycive Therapeutics Announces the Publication of Patient Perspectives on Phosphate Management in the Journal of Nephrological Science
Large pill size, high pill burden and palatability were identified as key barriers for phosphate binder adherenceLOS ALTOS, ...
Lucid raises Perspective Therapeutics stock target to $20
Capital Markets increased its price target on Perspective Therapeutics Inc (NYSE:CATX) shares to $20.00, up from the previous $15.00, while maintaining a Buy rating on the stock. The $259.2 million ...
Nasdaq3d
Unicycive Therapeutics Publishes Review on Patient Perspectives in Phosphate Management for Chronic Kidney Disease
Unicycive Therapeutics, Inc. has announced the publication of a review in the Journal of Nephrological Science that explores patient perspectives on phosphate management in chronic kidney disease ...
Demystifying Arcturus Therapeutics: Insights From 5 Analyst Reviews
In the assessment of 12-month price targets, analysts unveil insights for Arcturus Therapeutics, presenting an average target ...
Expert Outlook: Sangamo Therapeutics Through The Eyes Of 11 Analysts
Analysts have recently evaluated Sangamo Therapeutics and provided 12-month price targets. The average target is $8.09, accompanied by a high estimate of $10.00 and a low estimate of $2.00. Surpassing ...